Condition category
Cancer
Date applied
10/03/2015
Date assigned
17/03/2015
Last edited
10/06/2016
Prospective/Retrospective
Retrospectively registered
Overall trial status
Completed
Recruitment status
No longer recruiting

Plain English Summary

Background and study aims
Electrochemotherapy (ECT) is a treatment to get chemotherapy into cancer cells. Firstly, a chemotherapy drug (for example, cisplatin or bleomycin) is injected into the tumour. An electric pulse is then applied, altering the outer layer of the cancer cell and making it easier for the drug to enter. ECT is used to control of recurrent or new skin or mucosal cancers in the head and neck region that are not suitable for chemoradiation or surgery. The aim of this study is to test the performance of ECT as an alternative to standard palliative treatments for head and neck cancers. It is hoped that it will work as well as the standard treatments but without as many side effects.

Who can participate?
Adults (aged over 18) with recurrent, metastatic or primary head and neck cancer not suitable for surgery or chemoradiotherapy.

What does the study involve?
Each eligible participant receives an intravenous (i.v.) or intratumoral (i.t.) administration of bleomycin (a drug used for chemotherapy) at a very low dosage and 8 min after the i.v. injection or immediately after the i.t. injection the tumor cells receive an electric stimulation with specific needle electrodes (the process is called electroporation). The procedure can be done under local or general anaesthesia according to the position and the numbers of tumors that have to be treated. The tumor response is investigated after two months and all the patients with complete healing of the lesions have visits at 4, 8 and 12 months after treatment.

What are the possible benefits and risks of participating?
Patients who will partially or totally respond to this treatment are likely to live longer and have a better quality of life (less pain, less bleeding, less anatomical or functional compromise).

Where is the study run from?
This study is run in 6 University or Major Head and Neck Departments in Italy (Pavia), Denmark (Copenhagen), Netherlands (Amsterdam), Spain (Barcelona), UK (London) and Slovenia (Lubljiana).

When is the study starting and how long is it expected to run for?
June 2011 to September 2015

Who is funding the study?
IRCCS Policlinico San Matteo Foundation (Italy)

Who is the main contact?
Dr Giulia Bertino
giulia.bertino@tin.it

Trial website

Contact information

Type

Scientific

Primary contact

Dr Giulia Bertino

ORCID ID

http://orcid.org/0000-0003-2840-5184

Contact details

Dept. of Otolaryngology Head & Neck Surgery
University of Pavia
IRCCS Policlinico San Matteo Foundation
P.le Golgi 2
Pavia
27100
Italy
+39 (0)382 526 218
giulia.bertino@tin.it

Additional identifiers

EudraCT number

ClinicalTrials.gov number

Protocol/serial number

N/A

Study information

Scientific title

Local treatment of HN cancer by electrochemotherapy. Analysis of the efficacy of the procedure in tumor control and survival

Acronym

EURECA

Study hypothesis

The primary aim is the evaluation of tumor response (one target lesion) according to RECIST criteria (version 1.1) at 2 months follow-up; the secondary aims are the data evaluation about safety (toxicity) of the procedure, analysis of overall and progression free survival and quality of life. In case of execution of PET-CT another secondary aim will be the evaluation of PET-CT uptake change between pre treatment and 8 weeks post treatment.

Ethics approval

Bioethic Committee of the IRCCS Policlinico San Matteo Foundation, 24/11/2011, refs: 20110005216 & P-20110034090

Study design

Phase II observational study

Primary study design

Observational

Secondary study design

Longitudinal study

Trial setting

Hospitals

Trial type

Treatment

Patient information sheet

Not available in web format, please use contact details to request a participant information sheet

Condition

Recurrent, metastatic HN cancer or primary cancer in patients with severe co-morbidities and/or which only regular treatment with extensive morbidity is available

Intervention

Collection of the data about tumor response, safety, toxicity, survival and quality of life (QoL) of patients submitted to intravenous administration of 15000 IU BLM/m2 within 1 min, after 8 min electroporation (with Cliniporator and specific electrodes) of the lesion with a 1 cm of safe margin. Procedure has to be finished within 30 min.

4 weeks after procedure:
1. CT or MRI (same imaging as pre-operative evaluation)
2. Evaluation of tumor response in accordance with RECIST criteria (version 1.1)
3. Photographic documentation
4. QOL assessments (EORTC QLQ-C30, EORTC QLQ-H&N35, EQ_5D)
5. In case of residual disease a second ECT can be considered (if residual disease after the 2nd ECT other treatment options must be considered).

8 weeks after procedure:
1. CT or MRI and PET-CT
2. Evaluation of tumor response in accordance with RECIST criteria (version 1.1)
3. Photographic documentation
4. QOL assessments (EORTC QLQ-C30, EORTC QLQ-H&N35, EQ_5D)
5. Biopsy on indication
6. In case of residual disease a second ECT can be considered (if residual disease after the 2nd ECT other treatment options must be considered).
7. All the CR must be followed up at 4, 8, 12 months after treatment

Intervention type

Procedure/Surgery

Phase

Drug names

Primary outcome measures

Evaluation of tumor response (only one target lesion) at 2 months after the procedure

Secondary outcome measures

1. Safety (toxicity) of the procedure
2. Analysis of overall and progression free survival
3. “Quality of life” (EORTC QLQ-C30, EORTC QLQ-H&N35, EQ_5D)

The evaluation of the secondary aims will be performed at each follow-up visit till one year of follow up in case of complete responders or till the last follow up visit before exit the protocol in case of partial responders, stable or progressive disease or death or patient unwilling/unable to continue follow-up.

Overall trial start date

15/06/2011

Overall trial end date

30/09/2015

Reason abandoned

Eligibility

Participant inclusion criteria

1. Histologically verified cancer of any type
2. Progressive and/or metastatic disease
3. Primary disease not eligible for surgery for patient’s general conditions or for the need of extensive surgery
4. Patients must have offered standard treatments
5. Measurable lesions suitable for application of electric pulses
6. Age> 18 yrs
7. Performance status (Karnofsky ≥ 70; WHO ≤ 2)
8. Life expectancy> 3 months
9. Treatment free interval of at least 4 weeks after previously applied chemo- or radiotherapyto the target lesions
10. Patients must be mentally capable of understanding the information given and sign informed consent

Participant type

Patient

Age group

Adult

Gender

Both

Target number of participants

120

Participant exclusion criteria

1. Other symptomatic lesions not under control
2. Lesions not suitable for ECT (bony invasion, large vessels infiltration, etc.)
3. Acute lung infection
4. Symptoms of poor lung function necessitates DLCO and patient can not be treated if this is abnormal
5. Severe coagulation disorders not correctable
6. Previous allergic reactions to bleomycin
7. If cumulative dose of 240000 IU BLM/m2 was previously exceeded
8. Chronic renal dysfunction (creatinine> 150 µmol/L)
9. Pregnancy or lactation

Recruitment start date

01/11/2011

Recruitment end date

30/09/2015

Locations

Countries of recruitment

Denmark, Italy, Netherlands, Slovenia, Spain, United Kingdom

Trial participating centre

Department of Otolaryngology Head & Neck Surgery, University of Pavia, IRCCS Policlinico San Matteo Foundation
P.le Golgi 2
Pavia
27100
Italy

Trial participating centre

Dept. of Otolaryngology, Head and Neck Surgery, VU University Medical Center
Amsterdam
1007 MB
Netherlands

Trial participating centre

Oncologic Service Hospital Clinic
Barcelona
-
Spain

Trial participating centre

Dept. of Oncology, Dept. of Otolaryngology, Head Neck Surgery, Copenhagen University Hospital
Copenhagen
2100
Denmark

Trial participating centre

Dept. of Maxillofacial/Head Neck Surgery Royal Marsden Hospital
London
SW3 6JJ
United Kingdom

Trial participating centre

Dept. of Otolaryngology, University Clinical Center Institute of Oncology
Ljubliana
SI - 1000
Slovenia

Sponsor information

Organisation

IRCCS Policlinico San Matteo Foundation (Italy)

Sponsor details

c/o Prof. Marco Benazzo
Dept. of Otolaryngology Head & Neck Surgery
University of Pavia
IRCCS Policlinico San Matteo Foundation
P.le Golgi 2
Pavia
27100
Italy

Sponsor type

Hospital/treatment centre

Website

http://www.sanmatteo.org

Funders

Funder type

Research organisation

Funder name

IRCCS Policlinico San Matteo Foundation (Italy)

Alternative name(s)

Funding Body Type

Funding Body Subtype

Location

Results and Publications

Publication and dissemination plan

Intention to publish results of the EURECA protocol for skin cancer for the end of 2015 and for mucosal cancer for 2016.

Intention to publish date

Participant level data

Not expected to be available

Results - basic reporting

Publication summary

2016 results in: http://www.ncbi.nlm.nih.gov/pubmed/27267144

Publication citations

Additional files

Editorial Notes

10/06/2016: Publication reference added.